The National Institute for Health and Care Excellence (NICE) has approved a chimeric antigen receptor (CAR) T-cell therapy for adults with large B-cell lymphoma. The treatment significantly delays ...

A next-generation, anti-CD19 enhanced CAR T-cell therapy that secretes interleukin-18 achieved a response in 81% of lymphoma patients who failed previous CAR T-cell therapy. Duration of response was 9 ...

Breyanzi has shown significant efficacy and durable responses in patients with marginal zone lymphoma. Among adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, the phase 2 ...

SOUTH SAN FRANCISCO, Calif., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation chimeric antigen receptor (CAR) ...

An investigational induced pluripotent stem cell-derived CAR natural killer cell therapy was well tolerated both as monotherapy and in combination with rituximab among patients with B-cell lymphomas, ...

“The FDA approval of Breyanzi for relapsed or refractory marginal zone lymphoma further solidifies it as the leading CD19-directed CAR T cell therapy covering the broadest range of B-cell malignancies ...

B-cell lymphomas constitute a heterogeneous group of malignancies derived from B-lymphocytes, with diffuse large B-cell lymphoma (DLBCL) representing the most common subtype. Among these, double-hit ...

Incyte INCY announced positive top-line results from a late-stage lymphoma study of Monjuvi/Minjuvi (tafasitamab), a ...

How Does Columvi Work for DLBCL and LBCL? Columvi is a special type of molecule that can attach to two different types of cells. This is called a bispecific antibody. It attaches to CD20 proteins on ...

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced new results from the Phase 1b/2 EPCORE ® NHL-2 trial Arm 10 (NCT04663347), evaluating epcoritamab, a T-cell engaging ...